Nicox Second Quarter 2018 Business Update and Financial
Nicox Second Quarter 2018 Business Update and Financial Highlights | Press Release |
| Nicox Second Quarter 2018 Business Update and Financial Highlights |
| .............................................. July 17, 2018 - release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today provided operational highlights and upcoming milestones, as well as revenues and cash position for Nicox and its subsidiaries (the "Nicox Group") as of June 30, 2018. Michele Garufi, Chairman and Chief Executive Officer of Nicox, stated, "VYZULTA sales by our global partner Bausch + Lomb grew substantially in the second quarter, reflected by an increase of over 180% in net royalty received by Nicox compared to the first quarter of 2018 . Looking ahead to the remainder of 2018, we expect to add a second revenue stream for the future through the planned launch in the fall of ZERVIATE(TM) in the United States by our U.S. partner Eyevance, and advancing towards the initiation of Phase 2 clinical studies for NCX 470 and NCX 4251." Key Upcoming Milestones · Q3 2018: Planned start of Phase 2 clinical study for NCX 470 for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. · Fall 2018: Expected commercial launch of ZERVIATE TM (cetirizine ophthalmic solution), 0.24% in the United States by partner Eyevance Pharmaceuticals, LLC. · Q1 2019: Planned U.S. Investigational New Drug (IND) submission to the U.S. FDA for NCX 4251 to enable a Phase 2 clinical study in patients with acute exacerbations of blepharitis, following the successful, latest pre-IND meeting with the U.S. FDA in June 2018 (discussed below). Second Quarter 2018 and Recent Operational Highlights Research Collaboration with Ironwood Pharmaceuticals, Inc. In June 2018, we announced that we have entered into a research collaboration with Ironwood, focused on combining Ironwood's expertise in soluble guanylate cyclase (sGC) and our proprietary nitric oxide (NO)-donating research platform to generate novel compounds in order to identify potential new therapeutics for the treatment of certain ophthalmic conditions. Further pre-IND meeting held for NCX 4251. In June 2018, an additional pre-IND meeting was held with the U.S. FDA, which addressed specific questions on development, including the potential primary endpoints for the Phase 2 clinical study. Based on the FDA comments from this and previous meetings, we are finalizing the design of the first in human Phase 2 clinical trial evaluating the safety and efficacy of NCX 4251 versus a vehicle comparator in subjects with acute exacerbations of blepharitis. We plan to submit an IND in Q1 2019 to enable this Phase 2 clinical study. Presentation of scientific data at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting. In May 2018, we presented preclinical data on NCX 667, a lead molecule among our future generation stand-alone NO-donors, demonstrating the lowering of IOP in a robust, dose-dependent manner in various normotensive and hypertensive ocular models. Opening of new U.S. development office in Research Triangle Park, North Carolina. In April 2018, we announced our decision to relocate from our prior development office in Fort Worth, Texas, and to expand our presence in the United States to focus on the planned advancement of NCX 470 and NCX 4251 into Phase 2 clinical studies. Second Quarter 2018 Financial Highlights As of June 30, 2018, the Nicox Group had cash and cash equivalents of €32.6 million as compared with €36.3 million at March 31, 2018 and €41.4 million at December 31, 2017. Net revenue 1 for the second quarter of 2018 was €0.226 million, comprised exclusively of royalties on Q2 2018 sales of VYZULTA TM by global partner Bausch + Lomb, after deduction of royalty payments due by Nicox. The Group recorded no revenues for the second quarter of 2017. Only the figure related to the cash position of the Group as of December 31, 2017 is audited; all other figures of this press release are non-audited. References Net revenue consists of revenue from collaborations less royalty payments which corresponds to Net profit in the consolidated statements of profit or loss |
| About Nicox |
| Nicox S.A. is an international ophthalmic company, with two out-licensed commercial-stage products, developing innovative solutions to help maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel drug candidates that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products with approved U.S. New Drug Applications, VYZULTA(TM) (latanoprostene bunod ophthalmic solution), 0.024%, licensed worldwide to Bausch + Lomb, and ZERVIATE(TM) (cetirizine ophthalmic solution), 0.24%, licensed in the U.S. to Eyevance. In addition, our promising pipeline includes clinical stage assets based both on our proprietary NO-donating research platform and on the repurposing of existing molecules as well as a future generation of stand-alone nitric-oxide donors and exploratory novel NO-donating compounds with the potential to offer novel approaches to treat a range of ophthalmic conditions. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes. For more information on Nicox, its products or pipeline, please visit: www.nicox.com . |
| Analyst coverage |
| Bryan, Garnier & Co Hugo Solvet Paris, France Invest Securities Martial Descoutures Paris, France Gilbert Dupont Jamina EL Bougrini Paris, France | |
| The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. |
| Upcoming financial and business conferences |
| September 19 Goodwin, Solebury Trout European and Nasdaq European Biotech Investor Day New York, USA September 25-26 Oppenheimer Fall Summit New York, USA October 1-3 Cantor Global Healthcare Conference New York, USA November 22-23 Bryan, Garnier 6 th Annual Healthcare Conference Paris, France |
| Contacts |
| Nicox Gavin Spencer, Executive Vice President, Chief Business Officer T +33 (0)4 97 24 53 00 communications@nicox.com |
| Investor Relations Europe Nicox Corporate Communications Department T +33 (0)4 97 24 53 00 communications@nicox.com | Media Relations United Kingdom Jonathan Birt T +44 7860 361 746 jonathan.birt@ymail.com |
| United States Argot Partners Melissa Forst T +1 (212) 600-1902 melissa@argotpartners.com | France NewCap Nicolas Merigeau T +33 (0)1 44 71 94 98 nicox@newcap.eu |
| | United States Argot Partners David Rosen T +1 (212) 600-1902 david.rosen@argotpartners.com Italy Argon Healthcare International Pietro Pierangeli pietro.pierangeli@argonhealthcare.com Chiara Tettamanti chiara.tettamanti@argonhealthcare.com T. +39 02 4951.8300 |
| Disclaimer |
| The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the ' Document de référence, rapport financier annuel et rapport de gestion 2017 ' filed with the French Autorité des Marchés Financiers (AMF) on March 19, 2018, which is available on Nicox's website (www.nicox.com). |
| Nicox S.A. Drakkar 2 Bât D, 2405 route des Dolines CS 10313, Sophia Antipolis 06560 Valbonne, France T +33 (0)4 97 24 53 00 F +33 (0)4 97 24 53 99 |
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A banking overhaul is where glossy slides go to die. That is why GFT Technologies being named a Leader in QKS Group's 2026 SPARK Matrix for Digital Banking Services deserves a little more attention than the usual analyst-firm trumpet blast. This is not a prize for making a pretty mobile app. The work described here runs through strategy, architecture, core-platform...
Continue Reading
Numbers finally showed up wearing work boots in A. O. Smith’s latest sustainability report. The company says it beat every one of its three environmental targets, and the gaps were not the sort of rounding-error victories corporate communications teams love to polish until they shine. For investors following NYSE:AOS, that deserves a look—not a standing ovation, but a...
Continue Reading
Ninety-four lots in Conway may not move Wall Street by themselves, but they can say plenty about the kind of buyer Century Communities is chasing. Century Complete is opening its model at Cates Bay Crossing on Nov. 21, 2026, with single-family homes starting in the $260s. In a housing market where affordability gets talked to death and rarely delivered cleanly, that...
Continue Reading
July’s twin punches to Alphabet shares were not the sort of wobble investors can casually shrug off. First came a report on July 16 that Google was months behind on Gemini 3.5 Pro, its flagship AI model, after disappointing results from updated training data. Then came the harder financial reality a week later: a much larger 2026 capital-spending plan, negative...
Continue Reading
Radio gear finally caught a pulse in the third quarter, and that matters after more than two years of contraction. Dell’Oro Group says worldwide Radio Access Network revenue rose at a mid-single-digit year-over-year rate in 3Q 2026, the market’s strongest quarterly growth in nearly five years. That is better than expected, which is a welcome change in a telecom...
Continue Reading
A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...
Continue Reading
Enterprise software buyers hate renovations when a useful extension will do. Rox’s new integration with Microsoft Dynamics 365 Sales, announced November 19, 2026, is built around that unglamorous but very real fact. The company is not asking a Global 2000 sales organization to rip out its customer system, retrain everybody, and pray an AI layer somehow pays for the...
Continue Reading
A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...
Continue Reading
Three glossy-magazine nods may sound fluffy, but shelf momentum is never entirely fluff. Japanese haircare brand &honey says its Deep Moist Shampoo, Treatment and Hair Oil each landed 2026 recognition from Marie Claire, ELLE and Allure. For a consumer brand trying to make an American habit out of a Japanese haircare ritual, that is the sort of validation worth...
Continue Reading
Payroll sloppiness can turn a cheap burger shift into an expensive courtroom problem fast. Zakay Law Group, APLC has filed a proposed class action in Alameda County Superior Court against a long list of McDonald's franchise-related entities, alleging workers were not paid all wages due under California law. The case, 26CV218760, is pending, not proven, and that...
Continue Reading
Top 5 Most Recently Viewed Articles
Sweat and Laughter in the Big Apple Here we go again, folks! Degree Deodorant, the top dog in the antiperspirant world, is spicing up New York City's subway stations this summer. Now, I know what you're thinking: subway rides and deodorant—what a combo! But trust me, their new advertising campaign is a stroke of genius. It's inspired by those memorable, sweaty summer...
Continue Reading
Cupid's Senior Squad Ready to Share Dating Wisdom As Valentine's Day approaches, many look for meaningful advice on relationships and dating. Instead of relying on dating apps or self-proclaimed experts, you can trust the Cupid Senior Squad to provide wisdom gained over decades of love. Located at RiverSpring Living, this dedicated team is geared up to answer your...
Continue Reading
Understanding Short Interest for Intl Flavors & Fragrances International Flavors & Fragrances Inc (NASDAQ: IFF) has been experiencing notable fluctuations in its short interest, a key metric for investors. Recently, the company reported a decline of 5.37% in its short percent of float since the last update. Currently, 5.42 million shares are sold short, which constitutes...
Continue Reading
RFID Tags Market Size and Growth Projections The RFID tags market is on the rise, with projections indicating a market size of USD 29.05 billion by 2032. This growth stems from technological advancements and an increase in the adoption of RFID technology across different sectors. The market was valued at USD 12.42 billion in 2023, showcasing a compound annual growth rate...
Continue Reading
DataMesh Robotics Unveils a New Era in Industrial AI Training DataMesh, a prominent provider of digital twin technology and spatial intelligence solutions, has recently introduced DataMesh Robotics. This innovation is tailored to meet the needs of industrial and facility management scenarios, primarily through the use of embodied AI. The heart of this solution lies in the...
Continue Reading